
Jeny Maier, a member of Axinn’s Executive Committee, provides Fortune 500 companies pragmatic counsel on complex antitrust aspects of high-profile, multibillion-dollar transactions. She guides clients throughout the complete life cycle of transactions, from risk analysis and due diligence, to pre-merger notifications and merger agreement negotiations, through antitrust agency review, investigations, and remedies.
Recognized as a "Bright Rising Star" in antitrust law by The Legal 500 US and a "Future Leader" in competition law by Who's Who Legal, Jeny is lauded by her peers and clients as a “seasoned antitrust lawyer who advises companies in high-profile merger cases.” Among her many leadership roles, Jeny is Vice Chair of the American Bar Association Antitrust Law Section’s Serial Podcast Committee. Prior to joining Axinn’s executive leadership, she headed the firm’s Women’s Affinity Group.
Jeny leverages her background in economics to strategically assess commercial negotiations, regulatory risks and advocacy opportunities related to high-profile deals. She represents clients across industries, including the healthcare, pharmaceuticals, technology, manufacturing, telecommunications, and transportation sectors. Her experience includes advising Sunrun – a major provider of residential solar, battery storage, and energy services – on its transformational $3.2 billion acquisition of Vivint Solar.
In addition to her deal work, Jeny has considerable experience representing clients in civil and criminal antitrust investigations, and related class action litigation. She also advises clients on antitrust issues relating to pricing practices, distribution and marketing arrangements, intellectual property license agreements, and standard setting activities.
Before joining Axinn, Jeny was a senior associate in the antitrust practice of a global law firm. While attending the George Washington School of Law, she worked as a legal intern for the Federal Trade Commission’s Bureau of Competition and the US Department of Justice Antitrust Division’s National Criminal Enforcement Section.
Professional Activities
- American Bar Association, Antitrust Law Section, Serial Podcast Committee, Vice Chair (2022 – 2023)
- American Bar Association, Antitrust Law Section, Corporate Counseling Committee, Vice Chair (2019 – 2022)
- American Bar Association, Antitrust Law Section, Antitrust Law Developments, Editorial Board (2018 – 2019)
- American Bar Association, Antitrust Law Section, Civil Practice and Procedure Committee, Young Lawyers' Advisory Panel (2013 – 2017)
- American Bar Association, Health Law Section
- American Health Lawyers Association
Experience
Mergers and Acquisitions
- Representing McKesson in numerous matters, including a joint venture combining its US Oncology Research and HCA Healthcare Inc.’s Sarah Cannon Research Institute, its $875 million acquisition of Rx Savings Solutions, its $1.4 billion acquisition of CoverMyMeds, its $800 million acquisition of Medical Specialties Distributors (MSD), its $735 million acquisition of RxCrossRoads from CVS, its acquisitions of Labsco and Biologics, and its sale of Enterprise Information Solutions to Allscripts. Also secured clearance for McKesson’s $3.4 billion healthcare technology joint venture with Change Healthcare, which was unconditionally cleared after a Second Request investigation.
-
Represented Take-Two Interactive Software Inc. in its $12.7 billion acquisition of Zynga.
-
Represented Dell Technologies Inc. in its $4 billion sale of Boomi.
-
Represented Tufts Health Plan in its merger with Harvard Pilgrim Health Care.
-
Represented Sunrun in its $3.2 billion acquisition of Vivint Solar, securing clearance without a second request investigation.
-
Lead global coordinating antitrust counsel to Dell Inc. in its $67 billion acquisition of EMC Corporation.
-
Global antitrust lead counsel to Johnson Controls in the $2 billion sale of its Scott Safety business to 3M.
-
Represented Stanley Black & Decker Inc. in its $900 million purchase of the Craftsman brand from Sears Holdings Corporation.
-
Obtained clearance for Charles River Laboratories’ $585 million acquisition of WIL Research Laboratories.
-
Represented Tyler Technologies Inc. in its $670 million acquisition of New World Systems Corporation.
- Represented Interactive Data Corporation in its $5.2 billion acquisition by Intercontinental Exchange Inc.
- Represented SunGard in its $9.1 billion acquisition by Fidelity National Information Services Inc.
Litigation Experience
- Representing Independence Health Group (Independence Blue Cross) in a class action, multidistrict litigation (MDL) against the Blue Cross Blue Shield Association and individual Blue Cross and Blue Shield plans. The lawsuit, which alleges that the plans' designated service areas are anticompetitive, is the most significant challenge to the Blue System in its 80-year history.
- Represented RelayHealth, a subsidiary of McKesson, in a treble-damages class action alleging conspiracy to monopolize electronic prescribing services.
- Represented the Alliance for Safe Online Pharmacies in a treble-damages antitrust action alleging conspiracy to prevent PharmacyChecker.com from accessing internet platforms.
Honors
- Lawdragon, 500 Leading Dealmakers in America (2024)
- The Legal 500 United States, "Bright Rising Star" in Antitrust Law (2014)
- Who’s Who Legal Competition: Future Leaders (2017 – 2022)
- Profiles in Diversity Journal, Women Worth Watching (2018)
News
- Axinn Partners Named to 2024 Lawdragon 500 Leading Dealmakers in America
- Axinn Secures Early Summary Judgment on Behalf of the Alliance for Safe Online Pharmacies
- Axinn Advises McKesson on $875M Acquisition of Rx Savings Solutions
- Who's Who Legal Recognizes Ten Axinn Attorneys
- Axinn Advises McKesson on Joint Venture with HCA Healthcare
- View More ›
Thought Leadership
- Are PBMs Good For Competition? A Cost-Benefit Analysis of the Effects of Regulating Pharmacy Benefit Managers, ABA Our Curious Amalgam, October 2, 2023
- Can Competition and Quality Coincide? Analyzing a Systematic Competition Law Approach to Healthcare and Quality Concerns, ABA Our Curious Amalgam, September 25, 2023
- Amgen-Horizon Merger Clearance a Setback to FTC’s Antitrust Enforcement Plans, BioSpace, September 20, 2023
- Amgen, ICE Merger Settlements Mark FTC Pivot, The Deal, September 14, 2023
- What’s Happening in MENA? Trends and Developments in Middle East and Egyptian Antitrust, Our Curious Amalgam, July 24, 2023
- Illinois Cases to Watch in 2023: A Midyear Report, Law360, July 20, 2023
- Amgen/Horizon Therapeutics’ FTC Suit Carries Implications Beyond Pharmaceutical Mergers - Advisors, Mergermarket, June 27, 2023
- 'The Sleeping Giant is Waking Up': FTC Raises the Pressure on Pharma Dealmaking, Endpoints News, June 22, 2023
- An Agency in Peril? The Implications of Axon, Louisiana Children’s Medical Center, and Other Challenges to the FTC’s Power Audio Player, Our Curious Amalgam, June 19, 2023
- What’s Happening in Austria, Switzerland, and Lithuania? Conversations With Competition Law Enforcers at the 2023 Spring Meeting, Our Curious Amalgam, June 5, 2023
- In Pfizer-Seagen Review, FTC has Chance to Set New Pharma Precedent, BioPharma Dive, March 14, 2023
- A Sickness or a Cure for High Drug Prices? Why PBMs are Under the Antitrust Microscope, Our Curious Amalgam, March 13, 2023
- Antitrust Focus on PE Expands Beyond Just M&A, PE Hub, February 15, 2023
- A Power Grab Too Far? (Part 2) The European Commission Investigation in Illumina/Grail, Our Curious Amalgam, December 19, 2022
- DOJ Focus on Interlocking Directorates Reflects 'Shot Across the Bow' at PE – Analysis, Policy and Regulatory Report, December 9, 2022
- Who is Rahul Rao? Meet the Newest Deputy Director of the FTC Bureau of Competition, Our Curious Amalgam, November 14, 2022
- Biden’s Antitrust Crackdown: Five Things Dealmakers Should Know, PE Hub, September 12, 2022
- 2021's Biggest Antitrust Developments and What to Expect in 2022, AHLA Speaking of Health Law, January 18, 2022
- Major Merger Review Moments From 2021, Law360, December 21, 2021
- The Major Antitrust Conduct Cases of 2021, Law360, December 20, 2021
- New FTC Approach on Debt in Mergers Fuels Atty Uncertainty, Law360, October 7, 2021
- FTC's Withdrawal of Vertical Merger Guidelines Creates Uncertainty in U.S. Merger Policy, MLex, September 17, 2021
- FTC Withdraws 2020 Vertical Merger Guidelines. Will DOJ Follow Suit?, Compliance Week, September 16, 2021
- FTC to Take on Trump’s Vertical Merger Guidelines, Politico, September 15, 2021
- FTC Takes Up Strengthening Merger Review Reporting Requirements, Bloomberg Law, July 21, 2021
- A Tougher M&A Regulatory Environment, Pharma Manufacturing, June 25, 2021
- Health Care Antitrust Enforcement Homes in on Non-Hospital Transactions, AHLA PG Briefing, June 25, 2021
- AstraZeneca Hits U.K. Antitrust Review with $39B Alexion Buy After U.S. FTC Clearance, FiercePharma, May 25, 2021
- FTC's Crackdown on Pharma Mergers Reflects 'Tougher' M&A Environment Under Biden Administration: Lawyer, FiercePharma, March 22, 2021
- If You Can’t Beat Them and You Can’t Join Them: Geisinger and Evangelical’s Settlement with DOJ Limits the Scope of Their Partial Acquisition and Collaboration, AHLA Health Law Weekly, March 12, 2021
- Will the FTC Get Tougher on Pharma Business Practices Under the Biden Administration?, STAT, January 19, 2021
- If You Can’t Beat Them and You Can’t Join Them: Geisinger-Evangelical’s Warning for Partial Acquisitions, AHLA PG Briefing, January 4, 2021
- Buyer Beware: Considerations for a Divestiture Buyer in “Litigating the Fix”, 3 Antitrust Report 22, LexisNexis, November 2020
- UnitedHealth-DaVita and Trends in Vertical Merger Enforcement, AHLA PG Briefing, July 11, 2019
- How I Made Partner: Jeny Maier, Law.com, June 19, 2019
- Judge Moves Aetna / CVS Deal Into Unchartered Tunney Act Waters, Bloomberg Law, June 4, 2019
- The Capitol Forum Thought Leaders Series, April 25, 2019
- Vertical Healthcare Merger Review After United States v. AT&T, Inc., AHLA Weekly, July 27, 2018
- AHLA Antitrust Practice Group Alert, American Health Lawyers Association, March 27, 2018
Events
- GCR Live: Women in Antitrust 2023
- Draft Merger Guidelines – FTC and DOJ
- ACI 10th Annual Women Leaders in Life Sciences Law Conference
- Willis Towers Watson Healthcare Risk Conference 2023
- Life Sciences Dealmaking Faces More Antitrust Scrutiny
- AHLA Health Plan Law and Compliance Institute 2023
- AHLA Health Care Transactions Program 2023
- ABA National Managed Care Institute 2022
- GCR Live: Women in Antitrust 2022
- ACI 9th Annual Women Leaders in Life Sciences Law Conference
- CBA Competition Law Online Symposium
- ACI Life Sciences Antitrust 2021
- CompLaw Antitrust Texas Conference 2021
- ACI 8th Annual Women Leaders in Life Sciences Law Virtual Conference
- CompLaw Antitrust West Coast Virtual Conference 2021
- Axinn Webinar: Hot Topics in Health Care Deals – Key Takeaways from the AHLA Health Care Transactions and Antitrust Conferences
- AHLA Health Care Transactions Program 2021
- It Took a Pandemic: Professional and Personal Lessons from the Past Year
- ACI 7th Annual Women Leaders in Life Sciences Law Virtual Conference
- CompLaw Antitrust Texas Virtual Conference
- Recent Antitrust Developments in Healthcare & Pharma Q2 2020
- AHLA Virtual Annual Meeting
- ABA More Spring Blooms Series Webinar: Who Wants to be a Divestiture Buyer?
- CompLaw Antitrust Texas Conference
- Vertical Merger Enforcement: How to Effectively Navigate Through the Uncharted Waters of Complexities
- 2019 ABA Business Law Section Annual Meeting
- ACI 6th Annual Women Leaders in Life Sciences Law Conference
- Antitrust Issues for Government Contractors and the Defense Industry
- ACI 5th Annual Women Leaders in Life Sciences Law Conference
- A New Wave? Vertical Transactions in Healthcare Antitrust
- Hard Topics in Antitrust Risk Allocation
- Distribution Fundamental Series: Horizontal Arrangements
- ACI 4th Annual Women Leaders in Life Sciences Law Conference
- ABA Monthly Antitrust Update Program For In-House Counsel February 2016
Education
- JD – The George Washington University Law School (2005)
- BS – Georgetown University (2000)
Admissions
- District of Columbia
- New York
- US District Court District of Columbia
- US District Court Eastern District of New York
- US District Court Southern District of New York
Spotlight
"She stands out from her peers due to her pragmatic approach and outstanding client care."
– Who's Who Legal
"She is an in-house counsel's dream."
– Who's Who Legal
"She is very knowledgeable, very practical and very responsive."
– Who's Who Legal
Garners praise as "an excellent attorney and a wonderful person," and has extensive experience counselling clients in complex M&A transactions.
– Who's Who Legal
"[A] great competition lawyer with strong expertise in merger cases."
– Who's Who Legal
"Celebrated for her' knowledge and ability to provide clear and prescient insight into recent developments' in the field."
– Who's Who Legal